Clinical Manifestations and Prognosis of Chronic Kidney Disease after Hematopoietic Stem Cell Transplantation
Introduction: Kidney disease is a common complication of hematopoietic stem cell transplantation (HSCT). However, there is limited research on the clinical pathology and prognosis of patients who develop chronic kidney disease (CKD) after HSCT. Methods: A retrospective analysis was conduc...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-01-01
|
| Series: | Kidney Diseases |
| Online Access: | https://karger.com/article/doi/10.1159/000545198 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849321678355562496 |
|---|---|
| author | Yu Zhang Guisheng Ren Wencui Chen Jinzhou Guo Xiaomei Wu Weiwei Xu Xianghua Huang |
| author_facet | Yu Zhang Guisheng Ren Wencui Chen Jinzhou Guo Xiaomei Wu Weiwei Xu Xianghua Huang |
| author_sort | Yu Zhang |
| collection | DOAJ |
| description |
Introduction: Kidney disease is a common complication of hematopoietic stem cell transplantation (HSCT). However, there is limited research on the clinical pathology and prognosis of patients who develop chronic kidney disease (CKD) after HSCT. Methods: A retrospective analysis was conducted on 50 patients diagnosed with CKD through kidney biopsy between September 2008 and May 2024. The patients were categorized based on their pathological presentations into groups with thrombotic microangiopathy (TMA) or membranous nephropathy (MN). Results: The renal pathological results revealed that TMA was the most prevalent pathological type, accounting for 40% of cases, followed by MN at 32%, and mesangial proliferative glomerulonephritis at 16%, among others. Clinically, patients with TMA predominantly presented with renal insufficiency, whereas those with MN mainly exhibited nephrotic syndrome. Patients with MN showed favorable responses to treatment, achieving complete and partial response rates of 14.3% and 71.4%, respectively. Among the 50-patient cohort, 45 remained alive, corresponding to a 5-year overall survival rate of 87.8%. The 5-year renal survival rate was observed to be 78.8%, with 3 patients (6.98%) requiring kidney replacement therapy. Conclusion: TMA and MN are the two most common pathological findings in patients with CKD following HSCT. Both conditions exhibit favorable responses to combined steroids and immunosuppressant therapy. Notably, patients with MN demonstrate a higher overall response rate and superior treatment outcomes compared to those with TMA. |
| format | Article |
| id | doaj-art-2b6d07a6ca8a451798e670ee01933f79 |
| institution | Kabale University |
| issn | 2296-9357 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Kidney Diseases |
| spelling | doaj-art-2b6d07a6ca8a451798e670ee01933f792025-08-20T03:49:41ZengKarger PublishersKidney Diseases2296-93572025-01-0111119520510.1159/000545198Clinical Manifestations and Prognosis of Chronic Kidney Disease after Hematopoietic Stem Cell TransplantationYu ZhangGuisheng RenWencui ChenJinzhou GuoXiaomei WuWeiwei XuXianghua Huang Introduction: Kidney disease is a common complication of hematopoietic stem cell transplantation (HSCT). However, there is limited research on the clinical pathology and prognosis of patients who develop chronic kidney disease (CKD) after HSCT. Methods: A retrospective analysis was conducted on 50 patients diagnosed with CKD through kidney biopsy between September 2008 and May 2024. The patients were categorized based on their pathological presentations into groups with thrombotic microangiopathy (TMA) or membranous nephropathy (MN). Results: The renal pathological results revealed that TMA was the most prevalent pathological type, accounting for 40% of cases, followed by MN at 32%, and mesangial proliferative glomerulonephritis at 16%, among others. Clinically, patients with TMA predominantly presented with renal insufficiency, whereas those with MN mainly exhibited nephrotic syndrome. Patients with MN showed favorable responses to treatment, achieving complete and partial response rates of 14.3% and 71.4%, respectively. Among the 50-patient cohort, 45 remained alive, corresponding to a 5-year overall survival rate of 87.8%. The 5-year renal survival rate was observed to be 78.8%, with 3 patients (6.98%) requiring kidney replacement therapy. Conclusion: TMA and MN are the two most common pathological findings in patients with CKD following HSCT. Both conditions exhibit favorable responses to combined steroids and immunosuppressant therapy. Notably, patients with MN demonstrate a higher overall response rate and superior treatment outcomes compared to those with TMA. https://karger.com/article/doi/10.1159/000545198 |
| spellingShingle | Yu Zhang Guisheng Ren Wencui Chen Jinzhou Guo Xiaomei Wu Weiwei Xu Xianghua Huang Clinical Manifestations and Prognosis of Chronic Kidney Disease after Hematopoietic Stem Cell Transplantation Kidney Diseases |
| title | Clinical Manifestations and Prognosis of Chronic Kidney Disease after Hematopoietic Stem Cell Transplantation |
| title_full | Clinical Manifestations and Prognosis of Chronic Kidney Disease after Hematopoietic Stem Cell Transplantation |
| title_fullStr | Clinical Manifestations and Prognosis of Chronic Kidney Disease after Hematopoietic Stem Cell Transplantation |
| title_full_unstemmed | Clinical Manifestations and Prognosis of Chronic Kidney Disease after Hematopoietic Stem Cell Transplantation |
| title_short | Clinical Manifestations and Prognosis of Chronic Kidney Disease after Hematopoietic Stem Cell Transplantation |
| title_sort | clinical manifestations and prognosis of chronic kidney disease after hematopoietic stem cell transplantation |
| url | https://karger.com/article/doi/10.1159/000545198 |
| work_keys_str_mv | AT yuzhang clinicalmanifestationsandprognosisofchronickidneydiseaseafterhematopoieticstemcelltransplantation AT guishengren clinicalmanifestationsandprognosisofchronickidneydiseaseafterhematopoieticstemcelltransplantation AT wencuichen clinicalmanifestationsandprognosisofchronickidneydiseaseafterhematopoieticstemcelltransplantation AT jinzhouguo clinicalmanifestationsandprognosisofchronickidneydiseaseafterhematopoieticstemcelltransplantation AT xiaomeiwu clinicalmanifestationsandprognosisofchronickidneydiseaseafterhematopoieticstemcelltransplantation AT weiweixu clinicalmanifestationsandprognosisofchronickidneydiseaseafterhematopoieticstemcelltransplantation AT xianghuahuang clinicalmanifestationsandprognosisofchronickidneydiseaseafterhematopoieticstemcelltransplantation |